The prologation of the thrombotest clotting time in newborns by Kamulyak, K. et al.
 
 
 
The prologation of the thrombotest clotting time in
newborns
Citation for published version (APA):
Kamulyak, K., Devilee, P. P., Nieuwenhuizen, W., & Hemker, H. C. (1988). The prologation of the
thrombotest clotting time in newborns. Thrombosis Research, 52(1), 45-52. https://doi.org/10.1016/0049-
3848(88)90039-4
Document status and date:
Published: 01/01/1988
DOI:
10.1016/0049-3848(88)90039-4
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Jan. 2021
THROMBOSIS RESEARCH 52; 45-52, 1988 
0049-3848/88 $3.00 + .OO Printed in the USA. 
Copyright (c) 1988 Pergamon Press plc. All rights reserved. 
THE PROLONGATION OF THE THROMBOTEST CLOTTING TIME IN NEWBORNS 
K. Hamulygkl, P.P. Devild W. Nieuwenhuizen2 and H.C. Hemker' 
Department of Biochemistry', pdical Faculty, University of Limburg, the 
Netherlands. Gaubius Institute , TNO, Leiden, The Netherlands 
(Received 14.3.1988; accepted in revised form 2.8.1988 
by Editor M. Verstraete) 
ABSTRACT 
As judged from thrombotest dilution curves clotting inhibiting 
material was present in 67% of human umbilical cord plasma samples 
of healthy full term infants (n=40). The correlation coefficient 
(r-value) between the thrombotest clotting times and the pro- 
thrombin levels was -0.46. Using sensitive enzyme inrmuno assays 
for fibrin degradation products (WDP) and fibrinogen degradation 
products (FqDP), we found that no degradation products could be 
demonstrated in the non-inhibited group whereas small amounts of 
these products were present in the inhibited group. These small 
amounts were undetectable using conventional assays. The most 
striking finding was the presence of fibrin and fibrinogen degra- 
dation products. The prolorfgation of the thrombotest clotting time 
could be imitated by adding fibrinogen fragment X to umbilical 
cord plasma in which no clotting inhibiting material was present 
in the thrombotest dilution curve. We conclude that the thrombo- 
test clotting is of limited value in the assessment of the vitamin 
K-dependent coagulation factors_in umbilical cord plasma. As 
utmost care was taken to avoid prcreolytic breakdown in vitro, our 
findings most likely reflect an enhanced fibrino(geno)lytic 
activity in umbilical cord plasma in vivo. 
INTRODUCTION 
The vitamin K-dependent coagulation factors in full term, healthy newborns 
are at birth in the range of 20-60X of the values found in normal adults 
(1). A vitamin K deficiency can be held responsible for this in only a 
minority of the cases (2). Among the laboratory tests, often used in 
clinical practice, to obtain an impression of,a deficiencyRof the 
coagulation factors 11, VII and X, are Thrombotest and Normotest . These 
tests are variants of the classical prothrombin time, in the presence of 
excess factor V and fibrinogen. The exact composition of these reagents has 
not been published. Besides the amount of the coagulation factors II, VII 
and X, a number of other factors can also influence the thrombotest 
clotting time. Relatively short thrombotest clotting times are found, when 
the blood samples are stored for more than 2-4 hours in glass tubes at low 
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temperatures. This phenomenon is probably due to a factor XII dependent 
activation of factor VII (3) and is especially important in plasmas of 
women using oral contraceptive drugs (4). Relatively long thrombotest 
clotting times are found whenever one of the factors II, VII or X becomes 
rate limiting (congenitally or acquired deficiency, early in coumarin oral 
anticoagulant therapy), in the presence of a structurally abnormal factor 
IX (Haemophilia Bm) (5) or in the presence of other inhibitors such as 
heparin (6). descarboxy coagulation factor X (7), fibrin(ogen) degradation 
products (6) and in the case of excess citrate (8). 
Inhibition of the thrombotest clotting time, defined as a difference of at 
least 5 seconds in the so called thrombotest dilution curve has been 
described in 67% of human umbilical cord plasma samples of normal full term 
healthy newborns by our group (6). This inhibition could not be attributed 
to discrepancies between the individual coagulation factors II, VII and X, 
the presence of descarboxy coagulation factors, an excess of citrate or the 
presence of fibrin(ogen) degradation products as assessed using 
conventional relatively insensitive assays. The presence of heparin-like 
activity has been postulated, but could not be confirmed (9). Thrombotest 
clotting times are widely used as a screening test for the amount of the 
vitamin K-dependent coagulation factors present and by some authors 
recommended as a diagnostic tool for the diagnosis of a vitamin K 
deficiency in newborns (10). The aim of this study was to assess the value 
of the thrombotest clotting time in defining the levels of the vitamin 
K-dependent coagulation factors in newborns and to see if any other 
factor(s) might contribute to the prolongation of the thrombotest clotting 
time described in normal healthy newborns at birth. 
MATERIALS AND METHODS 
We investigated 40 umbilical cord plasmas of healthy, full term newborns. 
No vitamin K had been administered to the mother or the newborns, nor any 
medication, known to influence the normal haemostatic mechanism. In all 
cases, the apgar score was above 7 (at 1 minute) and the plasma pH above 
7.2; imnediately after b?rth the umbilical cord was clamped and blood drawn 
by a clean puncture of the umbilical vein. After discarding the first 2 ml, 
9 volumes of blood were mixed in a propylene tube with one volume of an 
anticoagulant mixture: 0.1 M trisodium citrate dihydrate, 15 mM sodium 
azide, 0.3 M hydroxyethylpiperazine ethane sulfonic acid (Hepes) and 1000 
KIE Aprotonin (Trasylol)/ml. Platelet poor plasma was obtained by 
centrifugation at 3000xg for 15 minutes and rendered platelet free by 
centrifugation at 2O.OOOxg for 30 minutes at 4 OC. The samples were frozen 
immediately at -80 'C in aliquots of 1 ml until further use. Plasma of 20 
adult donors was prepared in the same way to serve as a control normal 
adult pool. 
Thrombotest R and Normotest R reagents were obtained from Nyegaard, Oslo, 
Norway. The assays were performed exactly as indicated in the manufacturers 
prescription. Thrombotest dilution curves were made by plotting the 
thrombotest clotting times (Y-axis) against the corresponding dilution of 
plasma (X-axis). Plasmas were diluted in Michaelis buffer (0.15 M 
Na-Veronal, 0.1 M Na-acetate, 0.15 M NaCl) in plastic tubes immediately 
before they were tested. -411 measurments were made in duplicate. These 
curves have shown to be linear (11). At the intersection point in the 
Y-axis the concentration of the coagulation factors is "infinite high". If 
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inhibiting material is present, the degree of inhibition can be expressed 
in units as indicated in figure 1. The prothrombin levels (clotting 
activity) were measured with a one stage method using human thromboplastin 
and human prothrombin deficient plasma, using a computer program based on 
the clotting times of eight dilutions of adult normal pooled plasma (12). 
Thromborel (Boehringer Nannheim, GFR) was used as human thromboplastin. 
Human prothrombin deficient plasma (immunochemically depleted substrate 
plasma) was obtained from Diamed (Norat-Marten, Switzerland). 
Fibrin(ogen) degradation products in serum were determined using the 
conventional test kit of Wellcome (Thrombo-Wellco test kit, Wellcome Res. 
Lab Beckenham, England) and also in plasma using enzyme immuno assays 
(EIA's) based on monoclonal antibodies. Three different EIA's were used. In 
all three the capture monoclonal antibody is FDP-14 (13), which is specific 
for degradation products of fibrinogen (FgDP) and of fibrin (FbDP). The 
"Total degradation products" assay (TDP) measures the sum of FgDP and FbDP 
(14). Discrimination between the quantities of FgDP and FbDP is done by 
using different tagging antibodies, conjugated with horse radish peroxy- 
dase. In the FgDP-EIA, this is Y18 (15,16), whereas in the FbDP DD-13 is 
used (17). Purified fibrin(ogen) fragments were prepared as described 
previously for X (18), Y (19) and D-dimer (20). 
RESULTS 
In table I the mean values, range and SD are given of the Thrombotest 
clotting times, the Normotest clotting times and the prothrombin clotting 
activities (factor TIC) in cord plasmas from 40 healthy full term infants. 
TABLE I 
Assay N Mean value and SD Range 
Thrombotest Clotting Time(sec) 40 53.5" + 8.1 35.2 - 66.5 
Normotest Clotting Time(sec) 40 32.8" T 4.7 25.3 - 44.1 
Factor IIc (One Stage)(%) 40 50.6% z 12.2 28.8 - 73.7 
The correlation coefficient (r-value) between the thrombotest clotting 
times and the prothrombin levels was -0.46, between the normotest clotting 
times and the prothormbin levels -0.70. This indicates that especially the 
thrombotest clotting time does not give reliable information on the level 
of the vitamin K-dependent coagulation factor II (prothrombin). This could 
be due to the presence of an inhibitor. We could confirm data published 
previously by our laboratory that in 67% of the umbilical cord plasma 
samples of normal infants an inhibitor is found as judged from thrombotest 
dilution curves (6). An example is given in figure I. 
Fibrin(ogen) degradation products could not be demonstrated in any of the 
serum samples, using the test kit of Wellcome. The sensitivity of this 
method, however, is not very high (detection limit: 10 pg/ml). Moreover, 
some high molecular weight degradation products are thrombin clottable and 
will therefore not be measured in the conventional assay, which makes use 
of serum. With recently developed more sensitive EIA's that can be done in 
plasma we determined levels of FgDP, FbDP and TPD (FgDP+FbDP) in 6 umbili- 
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cal cord plasma with and in 6 without inhibiting material as judged from 
the thrombotest dilution curves. The results are summarized in Table II. 
The fibrin(ogen) degradation products are expressed as pg fibrinogen 
equivalent/ml. The large range of TDP detected in apparently normal babies 
must be regarded as interindividual variation, for instance due to the 
stress of the birth process. 
Figure 1: 
Thrombotest Dilutioncurves 
1.0-o adult normal pool 
2,Hnon-inhibitory cord 
plasma-pool 
3,minhibitory cord 
plasma (1 Unit) 
TABLE II 
Sample Degree of TDP FgDP FbDP 
Inhibition (U) 
; 
4 
6' 
Non inhibited 
cord plasma (n=6) 
adult plasma pool 
0.4 1.9 0.7 <0.25 
0.5 5.8 2.0 2.2 
0.5 0.7 <0.25 <0.25 
1.3 12.8 3.7 4.6 
0.3 2.2 0.5 <0.25 
0.3 1.8 <0.25 <0.25 
0 <0.25 <0.25 <0.25 
0 <0.25 <0.25 <0.25 
In the "inhibited samples small amounts of FbDP and FgDP were present, 
vhereas they were below the detection limit (0.25 $-in the non inhibited 
samples as well as in adult normal pool plasma. In order to see whether 
inhibition as observed in the thrombotest dilution curve could have been 
caused by fibrin(ogen) degradation products we added small amounts of 
purified degradation products X, Y or D-dimer to "non-inhibited" umbilical 
cord plasma and adult normal pooled plasma. In adults, the addition of a 
relatively high concentration of fragment X gave only a slight prolongation 
of the thrombotest clotting time (figure 2B). A more pronounced prolonga- 
tion was found in the "non-inhibited" umbilical cord plasma pool (figure 
2AJ. In adults as well as in newborns inhibition in the thrombotest 
dilution curves could be demonstrated by the addition of fragment X. 
Addition of the fragments Y and D-dimer in low concentrations did not 
affect the thrombotest-clotting times. 
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Figure 2A 
The effect of adding fragment X 
Figure 2B 
The effect of adding fragment X 
to non-inhibitory cord plasma to adult normal plasma in the 
in the thrombotest dilution curve thrombotest dilution curve 
l.oLo: non inhibitory cord plasma pool 1.~3: adult normal pool plasma 
2.w: 1 + 2.46 fig/ml fragment X 2.a-cl: 1 + 24.6 pg/ml fragment X 
3.w: 1 + 24.6 &/ml fragment X 
DISCUSSION 
In this study, we have provided data, that 
not a reliable tool to assess the vitamin K 
found previously (6) this is probably due 
the thrombotest clotting time is 
status of newborns. As has been 
to the fact that an inhibitory 
factor of the thrombotest clotting time is present in 67% of normal healthy 
infants at birth. Using sensitive EMS, we have demonstrated that degra- 
dation products both of fibrinogen and of fibrin are present in umbilical 
cord plasmas, which show an inhibitory factor as judged from the thrombo- 
test dilution curves. Degradation products could not be detected in the 
samples of the group in which the inhibitory factor was absent. Using 
conventional serum assays we were unable to detect fibrin(ogen) degradation 
products in umbilical cord blood, which is in agreement with the literature 
(21). This can be due to the fact that the conventional method is not 
sensitive enough and/or the possibility that high molecular weight 
fibrin(ogen) degradation products are partially thrombin clottable and will 
therefore not contribute to the amount of fibrinogen related antigen 
recovered in serum after complete clotting induced by thrombin and 
thromboplastin in the presence of aprotonin (Trasylol). The most striking 
finding was the presence of fibrinogen degradation products. This is only 
found in disease states with primary fibrinogenolysis or with treatment 
with thrombolytic agents. As we took care to minimize proteolysis in vitro, 
we feel that our data reflect an enhanced fibrino(geno)lytic acitivity in 
umbilical cord blood in vivo at birth. We were also able to induce the 
prolongation of the thrombotest clotting time and inhibition in the 
thrombotest dilution curve by adding small amounts of the purified 
fibrinogen degradation product, fragment X to the "non-inhibited" umbilical 
cord plasma pool and adult normal pool plasma. The effect of added fragment 
X appeared to be more pronounced in umbilical cord plasma. 
We conclude that the prolongation of the thrombotest clotting time in 
50 THROMBOTEST AND NEWBORNS Vol. 52, No. 1 
newborns is only partially due to low levels of the vitamin K-dependent 
coagulation factors II, VII and X and that the results of this test should 
not be taken as conclusive evidence for a vitamin K-deficiency, as is 
recommended by some authors in the literature (10). Too many factors, 
besides the levels of the vitamin K-dependent coagulation factors influence 
the results of this screening coagulation assay. As shown here also 
fibrin(ogen) degradation products contribute to the prolongation use of the 
thrombotest clotting time. Obviously, the limitation of the use of the 
thrombotest is even more pronounced, when the blood samples are not drawn 
carefully, and when adequate inhibitors of proteolysis in vitro are not 
present in the anticoagulant mixture in which the blood is collected. At 
present, the cause of the enhanced fibrin(ogeno)lytic activity of normal 
newborns at birth is not known. Fibrin(ogeno)lytic activity is the result 
of the relative activities of tissue plasminogen activator (tPA) and a fast 
acting tPA-inhibitor (22). Thus, increased fibrin(ogeno)lytic activity may 
be the result of an increased secretion of tPA from endothelial cells 
and/or a decreased level of tPA-inhibitor. The latter may be caused by 
increased levels of activated protein C (APC), which is known to decrease 
the activity of tPA-inhibitor (22). The enhanced fibrin(ogeno)lytic 
activity is probably one of the protactive mechanisms against the 
development of thrombosis in the umbilical cord vessels. 
It would be of interest to obtain our cord blood findings also in neonatal 
plasmas in the first week of life, because the nadir of he vitamin 
K-dependent coagulation factors is not usually at the time of birth but 2-3 
days later. This would strengthen our claim that our findings are relevant 
for the assessment of neonatal haemostasis. 
Unfortunately we are unable to obtain sufficient amounts of neonatal blood 
from healthy newborns, which is suited for haemostasis studies. 
REFERENCES 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
MONTGOMERY, R.R., MARLAR, R.A., GILL, J.C. Newborn haemostasis in: 
Clinics in Haematology, Sanders Corp. London, Philadelphia, Toronto, 
14(2) 443-455, 1985 
LANE, P.A., HATHAWAY, W.E. Vitamin K in infancy. J. of Pediatrics, 
106(3), 351-358, 1985 
ALTMAN, R., HEMKER, H.C. Contact activation in the extrinsic blood 
clotting system. Thromb. Diath. Haem. 18, 523-525, 1967 
HEMKER, H.C., MULLER, A.D., GONGRIJP, R. The estimation of activated 
human blood coagulation factor VII. J. of Mol. Med. 1, 127-131, 1976 
BERTINA, R.M., VELTKAMP, J.J. The abnormal factor IX of haemophilia 
B+variants. Thromb. and Haemost. 40, 335-338, 1978 
VAN WORM, J .M., MULLER, A.D., HFXKER, H.C. Heparin-like inhibitor, not 
vitamin K deficiency in the newborn. Lancet I, 852-853, 1977 
BERTINA, R.M. More than one type of factor X in plasma of patients 
using oral anticoagulants. Thromb.Haemostas. 47, 187-190, 1982 
Vol. 52, No. 1 THROMBOTEST AND NEWBORNS 51 
8. NAIMAN, J.L. Clotting and bleeding in cyanotic 
disease. J. of Pediatrics 76, 333-335, 1970 
congenital heart 
9. HAMULYAK, K. Aspects of the haemostatic mechanism in 
Maastricht, 20-22, 1985 
newborns. Thesis, 
10. SUZUKI, S. Studies on coagulation in newborn infants. 
229-234, 1979 
J. Perin. Med. 7, 
11. HEMKER, H.C., HEMKER, P.W. Kinetic aspects of the interation of blood 
clotting enzymes. Thromb. Diath. Haemorrh. 29, 364-369, 1968 
12. HEMKER, H.C., SWART, A.C.W., ALINK, A.M.J. Artificial reagents for one 
stage determination in the extrinsinc system. Thromb. Diath. Haemorr. 
27, 205-207, 1972 
13. KOPPERT, P.W., KOOPMAN, J., HAVERKATE, F., NIEUWENHUIZEN, W. Production 
and characterization of a monoclonal antibody reactive with a specific 
neoantigenic determinant in degradation products of fibrin and of 
fibrinogen. Blood 68, 437-441, 1986 
14. YOOPMAN, J., HAVERKATE, F., KOPPERT, P.W., NIEUWENHUIZEN, W., BROMMER, 
E.J.P., VAN DER WERF, W.G.C. New enzyme immuno assays of fibrin- 
fibrinogen degradation products in plasma using a monoclonal antibody. 
J. Lab. Clin. Med. 109, 75-84, 1987 
15. KOPPERT, P.W., HUYSMANS, C.M.G., NIEUWENHUIZEN, W. A monoclonal 
antibody, specific for human fibrinogen fibrinopeptide A-containing 
fragments and not reacting with free fibrinopeptide A. Blood 66, 
503-705, 1985 
16. KOPPERT, P.W., KUIPERS, W., HOEGEE-DE NOBEL, E., BROMMER, E.J.P., 
KOOPMAN, J., NIEUWENHUIZEN, W. A quantitative enzyme immuno assay for 
primary fibrinogenolysis products in plasma. Thromb. Haemost. 57, 
25-28, 1987 
17. KOPPERT, P.W., HOEGEE- DE NOBEL, E., NIEUWENHUIZEN, W. A monoclonal 
antibody-based enzyme immuno assay for fibrin degradation products in 
plasma. Thromb. Haemost, in print, 1988 
18. NIEUWENHUIZEN, W., GRAVESEN, M. Anticoagulant and calcium-binding 
properties of high molecular weight derivatives of human fibrinogen, 
produced by plasmin (fragments X). C 
313-316, 1982 
19. 
20. 
NIEUWENHUIZEN, W., VOSKUILEN, M., HERMAN'S, J. Anticoagulant and calcium 
binding properties of high molecular weight derivatives of human 
fibrinogen (plasmin fragments Y). Biochim. Biophys. Acta, 758, 317-320, 
1982 
VAN RUYVEN-VERMEER, T.A.M., NIEUWENHUIZEN, W., HAVERKATE, F., TIMAN, T. 
A novel method for the rapid purification of human and rat fibrin(ogen) 
degradation products. Hoppe-Seylen's Z. Physiol. Chemie, 360, 633-635, 
1979 
52 THROMBOTEST AND NEWBORNS Vol. 52,' No. 1 
21. NAIXAWAY, W.E. Fibrin split products in serum of newborns: possible 
technical errors. Pediatrics 45(l), 154-155, 1970 
22. VAN HINSBERGH, V.M.W., BERTINA, R.M., VAN WIJNGAARDEN, A. Activated 
protein C decreases plasminogen activator inhibitor activity in 
endothelial cell-conditioned medium. Blood 65, 441-443, 1985 
